Website update in progress

Following the transformation of Polpharma Biologics (learn more), this site will focus on biosimilars development in Switzerland. In Poland, we operate now as Rezon Bio – a contract developer and manufacturer of biologics (CDMO). More at www.rezonbio.com.

Due to the demerger of Polpharma Biologics into two independent companies (detailed information can be found in the “Knowledge center” section), the website polpharmabiologics.com is currently being updated. For details on the CDMO business, please visit the Rezon Bio website

Go to Rezon Bio website

Experienced leadership, global vision

Our leadership team brings decades of combined experience in biologics development, manufacturing, and commercialization. Passionate about patient impact and committed to operational excellence, they drive our mission forward every day.

Jerzy Starak

Founder and Owner Polpharma Biologics Group

Jerzy Starak is one of the Polish entrepreneurs whose activities contributed to the modernization and innovative development of the Polish economy. A visionary full of courage and determination in realizing ever new business challenges.

Jerzy Starak played a key role in the development of the Polish pharmaceutical sector. In 2000, he became the owner of Polpharma S.A. Ambitious modernization processes, huge investments in research and laboratory infrastructure and cooperation with top class specialists made Polpharma S.A. a European leader in the production of generic drugs.

In 2010, Jerzy Starak, inspired by the global direction in pharmaceutical development, made the decision to expand his business activities into production of biological drugs. Already in 2012, the first Research and Development Center opened in the Gdańsk Science and Technology Park and in 2020 another modern Center for Development and Production on an industrial scale began its activities in Warsaw-Duchnice. Today, Polpharma Biologics is the largest biosimilar drug development company in this part of Europe, operating in partnerships with global leaders in the pharmaceutical market.

Supervisory Board Polpharma Biologics Group

Emmanuelle Lepine

Chairwoman

Polpharma Biologics Group

“We are passionate about getting safe and effective medicines to patients”

Dr Joerg Windisch

Supervisory Board Member

Polpharma Biologics Group

“We value everyone equally and always treat each other with respect”

Michel Cup

Supervisory Board Member

Polpharma Biologics Group

“We care about being respectful and transparent”

Dr Konstantin Matentzoglu

Supervisory Board Member

Polpharma Biologics Group

“We work with dedication and find innovative solutions”

Gertjan Noordermeer

Supervisory Board Member

Polpharma Biologics Group

Management Board of Polpharma Biologics Switzerland AG

Emmanuelle Lepine

Chairperson of the Board

of Directors

Gertjan Noordermeer

Member of the Board

of Directors

Philipp Leitner

Member of the Board

of Directors

Hannes Teissl

Member of the Board of Directors

“We are passionate about getting safe and effective medicines to patients”

Dr Joerg Windisch

Member of the Board of Directors

The People Behind the Molecules

Alexander Pirc

Head Finance

Salima Fiandaca

Head Legal

Ruth Blättler

Head P&O

Anjan Selz

Chief Executive Officer

Emmanuelle Lepine

Chairwoman, Polpharma Biologics Group

Emma has over 25 years of experience in Pharma and Biotech, specializing in team leadership, B2B partnerships, and startup growth. She co-founded a biosimilar startup as Deputy CEO and later led a global biosimilar company as CEO. Her expertise in the Biosimilar industry makes her a valuable addition to our Supervisory Board. Emma, educated in Science and Business, hails from Canada and now resides in Spain.

Dr Joerg Windisch

Vice Chairman, Polpharma Biologics Group

“We are passionate about getting safe and effective medicines to patients”

Dr. Joerg Windisch has around 25 years of experience in the development, manufacture and regulatory licensure of biologic therapies. Since joining Polpharma Biologics, Dr. Windisch has made significant contributions to the organization’s formation and growth, and the development of its frontrunner products. Prior to joining Polpharma, Dr. Windisch served as the Chief Operating Officer (COO) for Affimed, a NASDAQ-traded biotech company which develops innovative bi- and trispecific antibodies as immune cell engagers to treat various kinds of cancer. Before that, Dr. Windisch spent almost 20 years at Novartis/Sandoz where he most recently served as Chief Scientific Officer (CSO) for Sandoz Biopharmaceuticals. He was a key figure in developing the first biosimilars approved in Europe and the US.

Michel Cup

Supervisory Board Member, Polpharma Biologics Group

“We value everyone equally and always treat each other with respect”

Michel Cup (52), a Dutch national, was EVP and CFO of Mead Johnson Nutrition based in Chicago until 2018, MJN is a global leader in pediatric nutrition. Since 2011 he was the CFO and Board member of DE Master Blenders 1753, (currently JDE Peets Coffee), a global pure coffee & tea player and was as CFO responsible for the carve out from Sara Lee in Chicago and the subsequent listing at the stock exchange in Amsterdam in 2012. He was closely involved in the merger with the Mondelez coffee activities after taking private in 2014. 
From 2009 until 2011 he was EVP and CFO of Provimi, a global Animal Nutrition company based in Rotterdam the Netherlands, which was acquired by Cargill end of 2011. 
Before that Michel served as CFO Asia Pacific for Numico (Danone), a pure play infant and adult nutrition company, where he was based in Singapore. Since 1999 he had several finance roles within Numico based in the US and The Netherlands. 
Michel started his career as a Chartered Accountant at Deloitte in the Netherlands. 
He has a post-doctoral degree from the University of Tilburg Netherlands.

Dr Konstantin Matentzoglu

Supervisory Board Member, Polpharma Biologics Group

“We care about being respectful and transparent”

Konstantin Matentzoglu is the Delegated Supervisory Board Member of Polpharma Biologics Group and a seasoned leader in biotechnology.

Throughout his career, he has led significant growth transformations in the life sciences sector.

He also serves on the boards of BSP Pharmaceuticals S.p.A. in Latina, Italy; Prediction Biosciences SAS in Lyon, France; and CDL Therapeutics GmbH in Cologne, Germany.

Formerly, he was CEO and Board Member of Celonic Group.

Gertjan Noordermeer

Supervisory Board Member, Polpharma Biologics Group

“We work with dedication and find innovative solutions”

A graduate of the VU University of Amsterdam, Gertjan has nearly 30 years’ experience of working for international corporations in finance. He has held CFO positions with increased responsibilities.

Before joining Windstorm, Gertjan served as CFO of the Polpharma Group and previously as CFO of Teva Pharmaceuticals Europe where he built up extensive knowledge and expertise in the pharmaceutical industry. Prior to that he held the position of CFO in Avebe U.A., with responsibility for Finance, Tax, Treasury and ICT.

In his various roles Gertjan’s responsibilities included company development by organic growth and acquisitions, designing innovative growth plans, post-merger integrations, cost optimization plans and design/implementation of new financial organizational structures and systems. A pragmatic team leader with the ability to think clearly under pressure, Gertjan is rated highly for quality performance, team impact and helping global organizations define their future strategies.